Company Nykode Therapeutics

Equities

NYKD

NO0010714785

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Ratings for Nykode Therapeutics

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Oslo Bors Other stock markets 10:45:00 2024-04-23 am EDT			5-day change	1st Jan Change
13.41 ^NOK	+1.90%		+4.03%	-37.34%

Apr. 19	Nykode Therapeutics Launches Phase 2 Clinical Trial for Cervical Cancer Vaccine	MT
Apr. 19	Nykode Therapeutics ASA Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer	CI

Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeuticsâ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.

Number of employees: 172

NOK in Million	2021	Weight	2022	Weight	Delta
Novel Vaccines and Immunotherapies 100.0 %	292	100.0 %	69	100.0 %	-76.39%

NOK in Million	2021	Weight	2022	Weight	Delta
United States 100.0 %	292	100.0 %	69	100.0 %	-76.39%

Managers	Title	Age	Since
Agnete Brunsvik Fredriksen FOU	Founder	47	06-12-31
Michael Engsig CEO	Chief Executive Officer	-	07-02-28
Harald Gurvin DFI	Director of Finance/CFO	49	21-05-02
Mikkel Wandahl Pedersen CTO	Chief Tech/Sci/R&D Officer	50	21-05-31
Karoline W. Schjetne CTO	Chief Tech/Sci/R&D Officer	-	17-07-31
Siri Torhaug CTO	Chief Tech/Sci/R&D Officer	-	19-12-31
Mette Husbyn CTO	Chief Tech/Sci/R&D Officer	-	17-09-30
Mona Welschof CTO	Chief Tech/Sci/R&D Officer	-	13-09-30
Louise Stubbe LAW	General Counsel	-	21-12-31
Peter Fatum PRN	Corporate Officer/Principal	-	20-12-31

Members of the board	Title	Age	Since
Bernd Seizinger BRD	Director/Board Member	67	-
Einar Jørgen Greve BRD	Director/Board Member	64	-
Jan Haudemann-Andersen BRD	Director/Board Member	-	-
Alf Gunnar Martin Nicklasson CHM	Chairman	69	21-12-21
Anne Michelle Whitaker BRD	Director/Board Member	56	-
Birgitte Volck BRD	Director/Board Member	61	21-05-04
Christian Åbyholm BRD	Director/Board Member	52	-
Anders Tuv BRD	Director/Board Member	46	-
Elaine Sullivan BRD	Director/Board Member	63	22-05-12

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	326,546,444	179,598,448 ( 55.00 %)	0	55.00 %

Name	Equities	%	Valuation
Jan Haudemann-Andersen 12.39 %	40,455,750	12.39 %	56 M kr
Rasmussen Family 10.62 %	34,680,750	10.62 %	48 M kr
Radiumhospitalets Forskningsstiftelse 7.367 %	24,057,000	7.367 %	33 M kr
Andenaes Family 5.422 %	17,705,175	5.422 %	25 M kr
NORDA ASA 2.449 %	7,996,755	2.449 %	11 M kr
Vatne Capital AS 2.281 %	7,450,000	2.281 %	10 M kr
Danske Invest Asset Management AS 2.178 %	7,112,344	2.178 %	10 M kr
Joh Johannson Eiendom AS 2.125 %	6,937,641	2.125 %	10 M kr
Ole Morten Halvorsen 1.997 %	6,519,525	1.997 %	9 M kr
Simen Thorsen 1.719 %	5,612,508	1.719 %	8 M kr

Nykode Therapeutics ASA

Oslo Science Park Gaustadalléen 21

0349, Oslo

+47 22 95 81 93

http://www.nykode.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

13.41 NOK

Average target price

43 NOK

Spread / Average Target

+220.66%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
NYKODE THERAPEUTICS	-37.34%	390M
VERTEX PHARMACEUTICALS INCORPORATED	-0.49%	103B
REGENERON PHARMACEUTICALS, INC.	+3.31%	96.73B
ARGENX SE	+1.66%	21.31B
BIONTECH SE	-16.16%	21.21B
GENMAB A/S	-6.82%	18.79B
WUXI APPTEC CO., LTD.	-41.41%	16.37B
BEIGENE, LTD.	-22.87%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+6.32%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.46%	10.98B

Bio Therapeutic Drugs